- Home
- SLVM vs MLTX Comparison
SLVM vs MLTX Comparison
Compare SLVM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLVM
- MLTX
- Stock Information
- Founded
- SLVM 1898
- MLTX 2021
- Country
- SLVM United States
- MLTX Switzerland
- Employees
- SLVM N/A
- MLTX N/A
- Industry
- SLVM Paper
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- SLVM Basic Materials
- MLTX Health Care
- Exchange
- SLVM Nasdaq
- MLTX Nasdaq
- Market Cap
- SLVM 2.4B
- MLTX 2.4B
- IPO Year
- SLVM N/A
- MLTX N/A
- Fundamental
- Price
- SLVM $52.94
- MLTX $39.01
- Analyst Decision
- SLVM Hold
- MLTX Strong Buy
- Analyst Count
- SLVM 3
- MLTX 8
- Target Price
- SLVM $85.67
- MLTX $77.71
- AVG Volume (30 Days)
- SLVM 338.3K
- MLTX 301.3K
- Earning Date
- SLVM 05-09-2025
- MLTX 05-12-2025
- Dividend Yield
- SLVM 3.40%
- MLTX N/A
- EPS Growth
- SLVM 45.44
- MLTX N/A
- EPS
- SLVM 6.82
- MLTX N/A
- Revenue
- SLVM $3,689,000,000.00
- MLTX N/A
- Revenue This Year
- SLVM N/A
- MLTX $103.42
- Revenue Next Year
- SLVM $0.14
- MLTX N/A
- P/E Ratio
- SLVM $7.76
- MLTX N/A
- Revenue Growth
- SLVM 0.11
- MLTX N/A
- 52 Week Low
- SLVM $51.60
- MLTX $31.42
- 52 Week High
- SLVM $98.02
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- SLVM 37.44
- MLTX 50.57
- Support Level
- SLVM $54.32
- MLTX $37.79
- Resistance Level
- SLVM $55.70
- MLTX $40.71
- Average True Range (ATR)
- SLVM 1.53
- MLTX 1.78
- MACD
- SLVM -0.03
- MLTX -0.02
- Stochastic Oscillator
- SLVM 8.19
- MLTX 58.61
About SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.